Tranexamic acid is a Small Molecule owned by Palisade Bio, and is involved in 9 clinical trials, of which 4 were completed, 2 are ongoing, and 3 are planned.

Tranexamic acid (LB-1148) acts as serine protease inhibitor. It inhibits the proteases driving multi-organ failure resulting from multiple forms of shock. This leads to the escape of digestive enzymes outside the digestive tract leading to autodigestion. These enzymes are then carried into the bloodstream and lymphatic system where they lead to multiple organ failures. The drug candidate by inhibiting autodigestion blocks the digestive enzymes and thereby alleviates the disease condition.

The revenue for Tranexamic acid is expected to reach a total of $159m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Tranexamic acid NPV Report.

Tranexamic acid is currently owned by Palisade Bio.

Tranexamic acid Overview

Tranexamic acid (LB-1148) is under development for the treatment of cardiovascular surgery complications, abdominal adhesions, postoperative ileus, coronavirus-associated acute respiratory distress syndrome (ARDS) and (pulmonary dysfunction) multiorgan dysfunction syndrome (MODS). The drug candidate is administered through oral route or via a nasogastric tube and also enterally. It acts by targeting serum protease. The drug candidate is developed based on the platform science of autodigestion. It was also under development for the treatment of cardiogenic shock, septic shock, hemorrhagic shock and hypovolemic shock.

It was also under development for the treatment of coronavirus disease 2019 (covid-19) associated acute respiratory distress syndrome, coronavirus disease 2019 (covid-19) pneumonia.

Palisade Bio Overview

Palisade Bio (Palisade), formerly, Seneca Biopharma Inc is a biopharmaceutical company that develops novel treatments for nervous system diseases. The company offers cell therapy treatment for ALS, ischemic stroke, spinal cord injury, multiple sclerosis, optic neuritis, Alzheimer’s disease, traumatic brain injury, peripheral nerve injury, diabetic neuropathy, lysosomal disease, Parkinson’s disease, huntington’s disease and cerebral palsy, among others. It provides drug treatment for depressive disorder, cognitive complication due to diabetes, post traumatic stress disorder, neurodegeneration and anti aging. The company develops methods to generate replacement cells from neural stem cells. It conducts investigational and discovery research on proprietary neural stem cell lines, neurogenic small molecule screening platform and neurogenic small molecule portfolio. Palisade is headquartered in Germantown, Maryland, the US.

The operating loss of the company was US$42.3 million in FY2021, compared to an operating loss of US$10.7 million in FY2020. The net loss of the company was US$26.6 million in FY2021, compared to a net loss of US$16.3 million in FY2020.

Quick View – Tranexamic acid

Report Segments
  • Innovator
Drug Name
  • Tranexamic acid
Administration Pathway
  • Enteral
  • Oral
Therapeutic Areas
  • Cardiovascular
  • Gastrointestinal
  • Infectious Disease
  • Other Diseases
Key Companies
  • Sponsor Company: Palisade Bio
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.